Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28677044 | 0.95 | CYP1A2 (0.62) | CYP1A2CYP2D6CYP3A4HIF1ASIGMAR1 | |
| SCHEMBL12451410 | 0.88 | CYP1A2 (0.51) | CYP1A2CYP2D6CYP3A4HIF1ASIGMAR1 | |
| SCHEMBL20612947 | 0.86 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP3A4HIF1ASIGMAR1 | |
| SCHEMBL19404392 | 0.85 | CYP2D6 (0.48) | CYP1A2CYP2D6CYP3A4HIF1ASIGMAR1 | |
| SCHEMBL23335790 | 0.84 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP3A4HIF1ASIGMAR1 | |
| SCHEMBL29356128 | 0.83 | CYP1A2 (0.40) | CYP1A2CYP2D6CYP3A4HIF1ASIGMAR1 | |
| SCHEMBL94736 | 0.83 | CYP1A2 (0.40) | CYP1A2CYP2D6CYP3A4HIF1ASIGMAR1 | |
| SCHEMBL13224414 | 0.83 | CYP1A2 (0.40) | CYP1A2CYP2D6CYP3A4HIF1ASIGMAR1 | |
| SCHEMBL15358762 | 0.81 | CYP2D6 (0.59) | CYP1A2CYP2D6CYP3A4HIF1ASIGMAR1 | |
| SCHEMBL8034574 | 0.80 | CYP1A2 (0.40) | CYP1A2CYP2D6CYP3A4HIF1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3887470-B1 | GLASS-RESIN COMPOSITE-BASED MULTI-COMPOSITE MATERIAL | MICHELIN & CIE (FR) | 2023-01-04 | — | — | EP | disclosed |
| EP-3887472-B1 | GLASS-RESIN COMPOSITE-BASED MULTI-COMPOSITE MATERIAL | MICHELIN & CIE (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-20220002194-A1 | GLASS-RESIN COMPOSITE-BASED MULTI-COMPOSITE MATERIAL | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2022-01-06 | — | — | US | disclosed |
| US-10800795-B2 | Borated benzoxazine for use in the synthesis of polybenzoxazine | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2020-10-13 | — | — | US | disclosed |
| US-20200115394-A1 | BORATED BENZOXAZINE FOR USE IN THE SYNTHESIS OF POLYBENZOXAZINE | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800795-B2 | Borated benzoxazine for use in the synthesis of polybenzoxazine | PBRM1, BRIX1, BMX | CYP1A2 277/4885CYP2D6 418/4885CYP3A4 533/4885 |
| US-20200115394-A1 | BORATED BENZOXAZINE FOR USE IN THE SYNTHESIS OF POLYBENZOXAZINE | PBRM1, BRIX1, BMX | CYP1A2 277/4885CYP2D6 418/4885CYP3A4 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.